Publication Name	World Journal of Gastroenterology
Manuscript ID	21231
Country	China

Received	2015-07-01 18:27
Peer-Review Started	2015-07-04 23:03
To Make the First Decision	2015-08-26 15:11
Return for Revision	2015-09-01 15:22
Revised	2015-10-27 14:17
Second Decision	2015-12-22 12:39
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-12-30 17:28
Articles in Press	2015-12-30 17:28
Publication Fee Transferred
Edit the Manuscript by Language Editor	2016-01-27 11:37
Typeset the Manuscript	2016-03-03 15:21
Publish the Manuscript Online	2016-04-03 18:51

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma
Manuscript Source	Unsolicited Manuscript
All Author List	Jiang Li, Yu Hou, Xiao-Bei Cai and Bin Liu
Funding Agency and Grant Number
Corresponding Author	Bin Liu, MD, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Kunming Medical University, No. 295 Xichang Road, Kunming 650032, Yunnan Province, China. 13888836057@163.com
Key Words	Hepatocellular carcinoma; Survival; Hepatic resection; Sorafenib; Recurrence
Core Tip	Barcelona Clinic Liver Cancer stage C patients with portal vein thrombus and Child-Pugh class A liver function who received sorafenib after surgical resection had significantly longer overall survival (37 mo vs 20 mo, p = 0.01) and significantly longer time to progression compared to patients who received only resection (29 mo vs 22 mo, p = 0.041). Our data suggested that better outcomes can be achieved with sorafenib after surgical resection, rather than sorafenib monotherapy.
Publish Date	2016-04-03 18:51
Citation	Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016; 22(15): 4034-4040
URL	http://www.wjgnet.com/1007-9327/full/v22/i15/4034.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i15.4034

Full Article (PDF)	WJG-22-4034.pdf
Full Article (Word)	WJG-22-4034.doc
Manuscript File	21231-Review.doc
Answering Reviewers	21231-Answering reviewers.pdf
Audio Core Tip	21231-Audio core tip.mp3
Biostatistics Review Certificate	21231-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	21231-Conflict-of-interest statement.pdf
Copyright License Agreement	21231-Copyright assignment.pdf
Institutional Review Board Approval Form or Document	21231-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	21231-Language certificate.pdf
Supplementary Material	Supplementary_Material_20150701160534.pdf
Peer-review Report	21231-Peer-review(s).pdf
Scientific Misconduct Check	21231-Scientific misconduct check.pdf
Scientific Editor Work List	21231-Scientific editor work list.pdf